Notes to the Consolidated Financial Statements for the Year Ended 30 June 2014 NOTE 26: BUSINESS COMBINATION – TACERE THERAPEUTICS INC. ACQUISITION IN OCTOBER 2012 (continued) Financial details of the business combination made in the previous financial year (year ended 30 June 2013) were: $ Fair value of consideration transferred  Consideration for the acquisition in October 2012 was the issue of 102,321,345 (pre-consolidation) shares in Benitec Biopharma Limited, plus a potential cash royalty on future licensing revenue  1,530,765 Recognised amounts of identifiable net assets  Property, plant and equipment  17,567 Cash and cash equivalents   138,760 Amount owing to Benitec Biopharma Limited   (126,882) Other liabilities   (1,976) Identifiable net assets  27,469 Goodwill on acquisition impaired in the June 2013 financial statements   1,503,296 Net cash inflow on acquisition   143,603 Acquisition related costs recognised as an expense in the Group corporate expenses  77,104 Post-acquisition loss of Tacere in the period to 30 June 2013  267,720 Post-acquisition loss of Tacere in the period to 30 June 2014  1,903 Page 40 Benitec Biopharma Ltd  Annual Report 2014